New data regarding the use of anti-vascular endothelial growth factor (VEGF) prophylaxis in patients with moderate to severe nonproliferative diabetic retinopathy without diabetic macular edema underscore the need for an evidence-based shift to proactive diabetic retinopathy (DR) treatment (rather than “watch and wait”). Guideline recommendations do not reflect the available treatments, and strategies to reduce anti-VEGF treatment burden (eg, treat-and-extend dosing, high-dose and novel agents, and novel products) continue to evolve and emerge, challenging clinicians to stay current and highlighting the need for individualized treatment and shared decision-making in DR treatment.

This collection of activities provides guidance for treatment of DR/diabetic macular edema (DME) with anti-VEGF agents, strategies to reduce anti-VEGF treatment burden (eg, treat-and-extend dosing, high-dose and novel agents, and novel products), and highlights the need for individualized treatment and shared decision-making in DR treatment.